Cartesian Therapeutics has announced positive topline results from its Phase IIb clinical trial evaluating Descartes-08, an autologous, mRNA-engineered chimeric antigen receptor T-cell therapy ...

Cartesian Therapeutics updates on Descartes ... Recent Pipeline Progress and Anticipated Milestones Announced Positive Updated Long-Term Results from Phase 2b Trial of Descartes-08 in Participants ...

Updated Phase 2a Open-Label Trial Results Cartesian today also announced positive updated results ... s recurring losses from operations and negative cash flows, substantial fluctuation in the ...

Cartesian Therapeutics, Inc. (NASDAQ: RNAC), (“the Company”) a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced positive twelve ...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) just reported positive results from its phase 2 study using Descartes-08 for the treatment of patients with Myasthenia Gravis [MG]. These positive ...

Analysts do not expect the company to be profitable this year, which aligns with the reported negative basic and diluted EPS (Earnings Per Share) of -55.74 USD and -55.78 USD, respectively. On a more ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Cartesian Therapeutics ... Additionally, positive results from the Phase 2b trial of Descartes-08 were announced ...

Updated Phase 2a Open-Label Trial Results Cartesian today also announced positive updated results ... s recurring losses from operations and negative cash flows, substantial fluctuation in the ...

FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering ...

Updated Phase 2a Open-Label Trial Results Cartesian today also announced positive updated results ... s recurring losses from operations and negative cash flows, substantial fluctuation in the ...